<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142284</url>
  </required_header>
  <id_info>
    <org_study_id>021-KOA-0901i</org_study_id>
    <nct_id>NCT01142284</nct_id>
  </id_info>
  <brief_title>Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety</brief_title>
  <official_title>Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety in Peripheral Artery Disease Subjects Complicated With Coronary Artery Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based upon evidence of efficacy and safety of both cilostazol and probucol administration in&#xD;
      independent randomized controlled trials in PAD and CAD, the present trial seeks to&#xD;
      investigate the effect of concomitant administration of cilostazol and probucol on FMD&#xD;
      compared to each drug individually, as well as to evaluate biomarker measures and safety&#xD;
      indices in this context.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary:&#xD;
&#xD;
        1. To evaluate the effect of concomitant administration of cilostazol and probucol on the&#xD;
           12-week change in FMD from baseline compared, with individual drugs alone.&#xD;
&#xD;
        2. To assess the safety of concomitant administration of cilostazol and probucol in&#xD;
           peripheral artery disease (PAD) subjects complicated with coronary artery disease (CAD)&#xD;
           as determined by physical examination, vital signs, adverse events (AEs), laboratory&#xD;
           tests, ECGs.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        1. To evaluate the effect of cilostazol and probucol administered concomitantly and as&#xD;
           individual drugs, compared with control, on changes in FMD from baseline to Weeks 6 and&#xD;
           12.&#xD;
&#xD;
        2. To evaluate the effect of cilostazol and probucol administered concomitantly and as&#xD;
           individual drugs, compared with control, on changes in metabolic, inflammatory,&#xD;
           oxidative, and platelet biomarkers from baseline to Weeks 6 and 12.&#xD;
&#xD;
        3. To evaluate the effect of cilostazol and probucol administered concomitantly and as&#xD;
           individual drugs, compared with control, on the time course (over the 12-week treatment&#xD;
           period) of changes in FMD and biomarkers levels.&#xD;
&#xD;
        4. To assess the effect of drug withdrawal on these endpoints at follow-up (from Week 12 to&#xD;
           Week 16).&#xD;
&#xD;
        5. To explore the relationship between changes in FMD and changes in the biomarker levels&#xD;
           at Week 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>On the 12-week change in FMD / Safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the effect of concomitant administration of cilostazol and probucol on the 12-week change&#xD;
To assess the safety of concomitant administration of cilostazol and probucol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the biomarker and FMD</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the effect of cilostazol and probucol administered concomitantly and as individual drugs, compared with control, on changes in FMD&#xD;
To evaluate the effect of cilostazol and probucol administered concomitantly and as individual drugs, compared with control on biomarkers&#xD;
To evaluate the effect of cilostazol and probucol administered concomitantly and as individual drugs, compared with control, on the time course&#xD;
To assess the effect of drug withdrawal&#xD;
To explore the relationship between changes in FMD and changes in the biomarker levels</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probucol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>probucol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilostazol + Probucol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol and probucol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol, Probucol</intervention_name>
    <description>Treatment Group 1 (control) No cilostazol or probucol&#xD;
Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID&#xD;
Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID&#xD;
Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_label>Cilostazol + Probucol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Probucol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age is ≥ 40 and &lt;80 years at Screening.&#xD;
&#xD;
          2. The subject has a diagnosis of PAD&#xD;
&#xD;
          3. The subject has a diagnosis of CAD&#xD;
&#xD;
          4. Stable background medical therapy over the past 3 months&#xD;
&#xD;
          5. Taking 100mg/day of aspirin or 75mg/day of clopidogrel over the past 3 months&#xD;
&#xD;
          6. Hyperlipidemia defined as a LDL cholesterol concentration &gt; 70 mg/dL&#xD;
&#xD;
          7. The subject is willing to participate in this study as documented by written informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New diagnosis of PAD within 3 months.&#xD;
&#xD;
          2. Currently taking cilostazol or has taken cilostazol&#xD;
&#xD;
          3. Currently taking probucol or has taken probucol within the last 3 months&#xD;
&#xD;
          4. Critical limb ischemia (CLI)&#xD;
&#xD;
          5. Congestive heart failure&#xD;
&#xD;
          6. Transient ischemic attack (TIA)&#xD;
&#xD;
          7. Endovascular peripheral or coronary revascularization procedure within 3 months&#xD;
&#xD;
          8. Coronary artery bypass graft (CABG) or major cardiovascular surgical procedures within&#xD;
             6 months&#xD;
&#xD;
          9. Major surgical procedures within 3 months&#xD;
&#xD;
         10. Uncontrolled hypertension&#xD;
&#xD;
         11. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus&#xD;
&#xD;
         12. Diabetic complications of severe peripheral neuropathy or active retinopathy.&#xD;
&#xD;
         13. Inflammatory bowel disease.&#xD;
&#xD;
         14. Unstable angina&#xD;
&#xD;
         15. QT prolongation&#xD;
&#xD;
         16. Severe or life threatening ventricular arrhythmias&#xD;
&#xD;
         17. History of syncope&#xD;
&#xD;
         18. Serum creatinine &gt; 2.5 mg/dL, Creatinine Clearance ≤25ml/min or renal failure&#xD;
             requiring dialysis.&#xD;
&#xD;
         19. History or evidence of any hematological or clotting disorder.&#xD;
&#xD;
         20. Hematocrit ≤ 28% or ≥ 55%.&#xD;
&#xD;
         21. AST or ALT &gt; 3 times the upper limit of normal (ULN).&#xD;
&#xD;
         22. Any form of chronic anticoagulation.&#xD;
&#xD;
         23. Coagulopathies defined as an INR &gt; 1.5&#xD;
&#xD;
         24. History of malignant disease within 5 years.&#xD;
&#xD;
         25. Acute or chronic hepatitis.&#xD;
&#xD;
         26. Hemophilia or known increased risk of hemorrhage.&#xD;
&#xD;
         27. Other clinically significant disorders resulting in a remaining life expectancy less&#xD;
             than one year.&#xD;
&#xD;
         28. Current alcohol or drug abuse.&#xD;
&#xD;
         29. If female, the subject cannot be pregnant or breastfeeding and must be of&#xD;
             non-childbearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SeungWhan Lee, MD.PhD.</last_name>
    <phone>02-3010-3170</phone>
    <email>seungwlee@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SeungWhan Lee, MD.PhD.</last_name>
      <phone>82-2-3010-3170</phone>
      <email>seungwlee@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>SeungWhan Lee, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>SW Hong/CTM</name_title>
    <organization>Korea Otsuka Pharmaceutical Co.,Ltd.</organization>
  </responsible_party>
  <keyword>Biomarker</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Flow Mediated Dilation</keyword>
  <keyword>Cilostazol</keyword>
  <keyword>Probucol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

